Emergency Use Authorization of a new drug for the treatment of COVID19


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
“A new drug for the treatment of COVID19 has got Emergency Use Authorization (EUA) by DCGI”

DCGI has given permission for the emergency use of the drug 2-deoxy-D-glucose (2-DG) for the treatment of COVID19. This drug is to be used only for hospitalized mild to moderate COVID19 patients. The drug is developed by collaboration of the Institute of Nuclear Medicine and Allied Sciences (INMAS), Defense Research and Development Organization (DRDO) and Dr. Reddy’s Laboratories. The drug comes in sachet form, to be dissolved in water and taken orally. The drug acts by mixing up with virus infected cells and thereby preventing virus growth by stopping viral synthesis and energy production. 

“It’s a selective accumulation in virally infected cells that make this drug unique. A higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients,” INMAS-DRDO said. 

According to INMAS-DRDO, results of clinical trial shows that this drug helps in faster recovery of hospitalized patients and reduces dependence on oxygen. This drug is expected to save valuable lives due to its mechanism of action (MOA). As it reduces the hospital stay, it will also help to lessen the load on health infrastructure.

As it is a generic drug and is easily available in our country hence, can be produced easily. The research was started in the first wave of pandemic last year April. Phase II trials were conducted on 110 patients in 17 hospitals. Results have shown a faster recovery and 2-3 days difference in normalizing the vital parameters. Clinical trial phase III results have shown improved conditions of patients significantly and reduced dependence on oxygen.

Tags : #Spotlight #EUA #2-DG #COVID19 #Drugforcovid #Medicircle #SmitaKumar #DCGI

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026